Amanda E Garza
@amandaegarza10
Scientist, Proud Texan living the dream in Boston!
ID: 1383212077
27-04-2013 00:43:31
1,1K Tweet
315 Takipçi
890 Takip Edilen
Hi folks - our lab in Dana-Farber Division of Population Sciences has an opening for a post-doctoral fellow at the interface of prostate cancer and AI via collab. with Dr. Mary-Ellen Taplin + Dana-Farber Lank Center for Genitourinary Oncology - link below! careers.dana-farber.org/job/10110/post… Dana-Farber Broad Institute Harvard Medical School
Women in STEM becoming independent: Embrace failures as part of the journey to success | Journal of Experimental Medicine | Rockefeller University Press. Great read & thanks Fern Koay 郭 & others for sharing your experiences & advice. rupress.org/jem/article/22…
Eliezer “Eli” Van Allen, MD (Eli Van Allen) has been named the inaugural incumbent of the Chandra Nohria Family Chair for AI in Cancer Research Dana-Farber.
Hello #MedTwitter! I’m Eddy Saad, a USJ graduate 🇱🇧 and currently a postdoc fellow studying kidney cancer and immunotherapy 🤓 Dana-Farber Harvard Medical School Incredibly grateful for the opportunity to be applying for the #InternalMedicine #Match2025 ! AAMC ID: 16349429 #IMG
Hi folks, we have new faculty open search in Dana-Farber Division of Population Sciences Dana-Farber Harvard Medical School, seeking folks interested in launching an independent research program across our very diverse and interdisciplinary set interests! See link for more info: careercenter.asco.org/job/7622758/as…
Sharing our latest work Journal of Experimental Medicine! We've uncovered that P2RX7 regulates unconventional T cells selectively, particularly subsets that co-produce IFN-γ & IL-4. Hoping this helps more discoveries in the role of these innate-like cells, using inhibitors from the P2RX7/ARTC2 field!
If you are in the Boston area and interested in neuroendocrinology research then this is for you :) Come join us next Monday for the Neuroendocrine Dialogs with two talks from @NatMachado_PhD lab about the brain circuits regulating thermoregulation HarvardBrainScience
Riaz Gillani, MD, and Ryan Collins in Eli Van Allen Dana-Farber report in Science Magazine that rare germline genetic abnormalities increase the risk of pediatric solid cancers, findings that could help improve treatments and screening. ➡️ bit.ly/3BQ04hK
The Dolan lab is recruiting a postdoc to work on mechanotherapeutic platforms to treat a range of diseases. I may be biased but this is a great lab to be in 🤗 see ad below 👇🏻 Ollscoil na Gaillimhe | University of Galway Biomedical Engineering University of Galway
🚀Excited to share our new paper, now published in Nature Communications! ✨ We present BEANIE, a nonparametric method that reduces false positives when analyzing differential gene signature expression in multi-patient clinical scRNA-seq cohorts Eli Van Allen 🧪🧵nature.com/articles/s4146…
Excited to share our new paper, "New horizons at the interface of artificial intelligence and translational cancer research", out now in Cancer Cell ! With Eli Van Allen, we explore how AI is reshaping oncology—from discovery to the clinic. 🔗 sciencedirect.com/science/articl…
We are looking for a candidate to apply for the FRM postdoctoral fellowship in late May. Join the thyroid cancer genetics and biology group at Gustave Roussy Research 🔬 ! If interested, check attachment and email me at [email protected] drive.google.com/file/d/1qY1rtI…
👏 Way to go Josephine Yates and Camille, and Eli Van Allen Valentina Boeva ! Excited to see this collaboration published—single-cell, epigenomic, and spatial profiling, oh yeah 💪🔬🧬! Dana-Farber News Broad Institute
So proud of Safa Bouabid!! Happy to see this beautiful piece of work finally out and even more excited for what’s next! She is on the job market and brings creativity, rigor and kindness to everything she does, and she’s a fantastic mentor. Reach out to her if you’re hiring!! :)
T-DXd may be a new 1L option for HER2+ metastatic #breastcancer, but which other pts could benefit? Ongoing trials are studying T-DXd in combo with endocrine and targeted therapies as well as in HER2 null disease and early-stage/residual disease. Thanks OncLive.com for hosting!